216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort.
Saved in:
| Title: | 216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort. |
|---|---|
| Authors: | Tredan, O.1 (AUTHOR), Saada, E.B.2 (AUTHOR), Dalban, C.3 (AUTHOR), Cousin, S.4 (AUTHOR), Le Cesne, A.5 (AUTHOR), Italiano, A.6 (AUTHOR), Bertucci, F.7 (AUTHOR), Gomez-Roca, C.A.8 (AUTHOR), Eberst, L.9 (AUTHOR), Ray-Coquard, I.L.10 (AUTHOR), Verlingue, L.11 (AUTHOR), Cassier, P.12 (AUTHOR), Attignon, V.K.13 (AUTHOR), Chabaud, S.14 (AUTHOR), Mayet, R.15 (AUTHOR), Cauquil, E.16 (AUTHOR), Fournier Garin, G.3 (AUTHOR), Perol, D.17 (AUTHOR), Blay, J-Y.18 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS291-S292. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.648 |
